Immuneering Statistics
Total Valuation
Immuneering has a market cap or net worth of $238.33 million. The enterprise value is $75.75 million.
| Market Cap | 238.33M |
| Enterprise Value | 75.75M |
Important Dates
The last earnings date was Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immuneering has 64.76 million shares outstanding. The number of shares has increased by 81.94% in one year.
| Current Share Class | 64.76M |
| Shares Outstanding | 64.76M |
| Shares Change (YoY) | +81.94% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 14.10% |
| Owned by Institutions (%) | 50.05% |
| Float | 49.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.97, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.97 |
| Quick Ratio | 13.47 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.53% and return on invested capital (ROIC) is -22.85%.
| Return on Equity (ROE) | -33.53% |
| Return on Assets (ROA) | -21.80% |
| Return on Invested Capital (ROIC) | -22.85% |
| Return on Capital Employed (ROCE) | -43.01% |
| Weighted Average Cost of Capital (WACC) | 6.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.02M |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.59% in the last 52 weeks. The beta is 0.46, so Immuneering's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -42.59% |
| 50-Day Moving Average | 4.12 |
| 200-Day Moving Average | 4.78 |
| Relative Strength Index (RSI) | 46.22 |
| Average Volume (20 Days) | 766,738 |
Short Selling Information
The latest short interest is 16.32 million, so 25.21% of the outstanding shares have been sold short.
| Short Interest | 16.32M |
| Short Previous Month | 15.49M |
| Short % of Shares Out | 25.21% |
| Short % of Float | 33.13% |
| Short Ratio (days to cover) | 22.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -73.88M |
| Pretax Income | -66.50M |
| Net Income | -66.50M |
| EBITDA | -73.52M |
| EBIT | -73.88M |
| Earnings Per Share (EPS) | -$1.03 |
Balance Sheet
The company has $145.41 million in cash and $3.53 million in debt, with a net cash position of $162.58 million or $2.51 per share.
| Cash & Cash Equivalents | 145.41M |
| Total Debt | 3.53M |
| Net Cash | 162.58M |
| Net Cash Per Share | $2.51 |
| Equity (Book Value) | 168.68M |
| Book Value Per Share | 2.60 |
| Working Capital | 139.92M |
Cash Flow
In the last 12 months, operating cash flow was -$61.56 million and capital expenditures -$246,365, giving a free cash flow of -$61.81 million.
| Operating Cash Flow | -61.56M |
| Capital Expenditures | -246,365 |
| Depreciation & Amortization | 357,139 |
| Net Borrowing | n/a |
| Free Cash Flow | -61.81M |
| FCF Per Share | -$0.95 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immuneering does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -81.94% |
| Shareholder Yield | n/a |
| Earnings Yield | -27.92% |
| FCF Yield | -25.93% |
Analyst Forecast
The average price target for Immuneering is $17.00, which is 361.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.00 |
| Price Target Difference | 361.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |